Review

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series

Giovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, Roberto Rosenfeld, Simona Guerriero, Manuela Carlucci, Barbara Capotondi, Francesco Torino and Mario Roselli

Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
* Correspondence: torino@med.uniroma2.it; Tel.: +39-0620908190

Abstract: The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarcomas, lung, and salivary gland cancer. However, as next-generation sequencing assays are increasingly available in the clinical setting, health care professionals may be able to detect NTRK gene fusions in patients affected by tumor types under or not represented in the clinical trials. To this aim, we systematically reviewed MEDLINE from its inception to 31 August 2022 for case reports and case series on patients with NTRK gene fusion-positive tumors treated with TRK inhibitors. A virtual cohort of 43 patients was created, excluding those enrolled in the above-mentioned clinical trials. Although our results align with those existing in the literature, various cases of central nervous system tumors were registered in our cohort, confirming the benefit of these agents in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by tumor types under or not represented in the clinical trials.

Keywords: NTRK gene fusions; TRK inhibitors; agnostic therapy; precision medicine

1. Introduction

1.1. Rationale

In the last decade, the advent of precision medicine has revolutionized the treatment landscape of several solid tumors [1]. The rapidly expanding knowledge in genomics, proteomics, and transcriptomics has led to the discovery of new molecular alterations and markers of immune phenotypes shared by multiple tumor types regardless of their site of origin [2]. In this scenario, the availability of pharmacological agents specifically and selectively targeting those alterations and markers has led to the approval of the so-called “histology-agnostic” drugs [3]. This new therapeutic approach has determined a paradigm shift in cancer treatment, paving the way for a new class of biomarker-driven anticancer agents that transcend tumor histologies [4]. Since 2017, the Food and Drug Administration (FDA) has approved six anticancer agents with a “histology-agnostic” indication: two immune checkpoint inhibitors (for both cancers with high tumor mutational burden or mismatch-repair deficiency/microsatellite instability) [5–7] and four targeted therapies (for tumors harboring a BRAF V600E mutation or a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) [8–10].

The NTRK gene family is composed of three members (NTRK1, NTRK2, and NTRK3) that encode for three tropomyosin receptor kinases (TRK) (TrkA, TrkB, and TrkC, respectively), physiologically involved in the development of the central and peripheral nervous system [11]. The occurrence of NTRK gene rearrangements determines a constitutive
activation of TRK receptors, potentially leading to cancer cell transformation [11]. In this framework, several studies have recently demonstrated that these alterations are oncogenic drivers of several tumors [12]. They can be detected with high frequencies (up to 90%) in some rare cancers (secretory breast carcinoma, mammary analogue secretory carcinoma, congenital infantile fibrosarcoma) and with lower frequencies (less than 1%) in a range of common adult patients’ cancers (non-small cell lung, colorectal, thyroid, and salivary gland cancers) [13].

Two oral targeted agents are currently available for unresectable locally advanced or metastatic cancer patients harboring an NTRK gene fusion: larotrectinib [9] and entrectinib [10]. The former was approved in 2018, based on the results of a prespecified combined analysis of three clinical trials published by Drilon et al. [14]. The latter was approved in 2019, after the publication of a pooled analysis of three clinical trials by Doebele et al. [15].

Although the above clinical trials enrolled patients with NTRK gene fusion-positive tumors regardless of their site of origin, most were affected by soft tissue sarcomas, lung, and salivary gland cancer [14,15]. In contrast, some tumor types were under or not represented, such as gastrointestinal (except for colorectal cancer), genitourinary, and gynecological malignancies [14,15]. However, as genomic medicine is constantly evolving, next-generation sequencing (NGS) assays for comprehensive genomic profiling have become increasingly available in clinical and research settings [16]. Therefore, health care professionals may have the chance to detect an NTRK gene fusion even in patients with tumor histologies under or not represented in clinical trials [14,15], thus facing the opportunity to provide patients with TRK inhibitors despite a lack of data.

1.2. Objective

To this aim, we evaluated the benefit of TRK inhibitors in a virtual cohort of patients affected by NTRK gene fusion-positive solid tumors derived from case reports (CR) and case series (CS) available in the literature. Although CR and CS are characterized by a high risk of biases due to their nature, they have consistently advanced medical knowledge on rare conditions, providing helpful information for clinical practice. To our knowledge, CR and CS on cancer patients harboring an NTRK gene fusion and treated with TRK inhibitors have never been systematically reviewed.

2. Methods

2.1. Protocol and Registration

The literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for systematic reviews [17] (Supplementary Material S1). The protocol was designed a priori by all the authors and was registered on the Open Science Framework website (https://osf.io/ngz6s/ [accessed on 1 October 2022]).

We included CR and CS on pediatric and adult patients affected by locally advanced or metastatic NTRK gene fusion-positive solid tumors treated with larotrectinib or entrectinib. Only publications in English or European languages were considered. Furthermore, CS were deemed eligible only if single-case descriptions were provided. Letters to the editor or other types of publications reporting CR or CS were also considered if they satisfied all the previous criteria. On the contrary, CR and CS on NTRK gene fusion-positive solid tumor patients treated with TRK inhibitors not yet approved by the FDA were excluded. In addition, eligible publications reporting on patients enrolled in the clinical trials that led to the approval of larotrectinib and entrectinib were excluded, as well [14,15]. Indeed, this systematic review aimed to create a virtual cohort of patients different from the populations enrolled in the clinical trials. Finally, patients who received TRK inhibitors through an early access program or were enrolled in observational or non-interventional clinical trials (e.g., post-marketing safety surveillance studies) were considered eligible.
2.2. Search

The electronic PubMed database was searched from inception to 31 August 2022 to identify all relevant publications. No research filters were used. The search strategy was decided on after a discussion among the authors. It was composed of four different syntaxes that were consecutively evaluated: (i) larotrectinib AND (case report OR case series); (ii) entrectinib AND (case report OR case series); (iii) larotrectinib AND NTRK; (iv) entrectinib AND NTRK. The results were uploaded to a reference management software (Zotero), and duplicates were later removed.

Two groups of three authors (G.M.I., M.C., S.G. and S.R., S.G., B.C.) independently scrutinized the available results following a two-stage study selection process. Firstly, all titles and abstracts were screened for potential relevance. Secondly, full texts of potentially appropriate results were retrieved and further assessed for eligibility. An agreement of the three authors of each group was required for exclusion at both stages. At the end of the selection process, the two groups discussed the list of publications to include in the review. In parallel, all the references of eligible studies were also hand-searched for other potential publications. In case of disagreements on the study selection, a consultation with two additional authors (M.R. and F.T.) was required. Finally, the two groups of authors achieved a complete consensus on the included papers and reported the results in the PRISMA flow diagram [17].

2.3. Data Charting Process

Three authors (G.M.I., S.R., F.T.) created a data charting template using Microsoft Excel software. As in the study selection process, the two groups of authors charted the data independently, discussing the results in an interactive process. Once a CS was analyzed, the single-case data were extracted individually. Disagreements in the charting process required consultation with two additional authors (M.R. and F.T.) and were resolved by consensus.

The variables extracted were: first author, journal of publication, year of publication, type of evidence (CR or CS), age and sex of the patient, primary tumor type, histological subtype, site of metastases (before being treated with NTRK inhibitors), NTRK gene fusion diagnostic modality, type of NTRK gene fusion, previous treatments, type of TRK inhibitor received, best radiological response (according to Response Evaluation Criteria in Solid Tumors (RECIST)), and outcomes.

Variables charted from eligible publications were described using numbers and proportions for categorical variables while mean, standard deviation, median, and interquartile range were used for continuous variables. The descriptive analyses were performed using R Studio (version 1.4.1106) software. Quantitative analyses were performed considering the overall population composed of both adult and pediatric patients, as reported in the clinical trials that led to the approval of larotrectinib and entrectinib. No inferential or predictive statistics analyses were performed.

2.4. Risk of Bias Assessment

The risk of bias assessment of included publications was performed using the methodological tool proposed by Murad et al. [18]. The two groups of authors responsible for the “selection process” assigned a binary response (yes = 1 and no = 0) to every question required by the tool. Subsequently, an aggregated score was formulated for each included CR or CS. In case of disagreements, a consultation with two additional authors (M.R. and F.T.) was required.

3. Results

3.1. Study Characteristics

The results of the literature search and the study selection process are displayed through a PRISMA diagram in Figure 1.
3. Results

3.1. Study Characteristics

The results of the literature search and the study selection process are displayed through a PRISMA diagram in Figure 1.

Figure 1. Flowchart of the results of literature search and selection process of included publications.

* Larotrectinib AND (case report OR case series).
† Entrectinib AND (case report OR case series).
§ Larotrectinib AND NTRK.
** Entrectinib AND NTRK. Abbreviations: Case report (CR), Case series (CS).

A total of 38 publications were included in this systematic review: 32 CR and 6 CS. They were published between 2018 and 2022 (Figure 2). Particularly, 21 CR and 2 CS reported about adult patients, while 11 CR and 4 CS were on pediatric patients. All the publications were written in English. Among the ineligible publications, 28 CR/CS were excluded because they reported data about patients enrolled in the clinical trials that led to the approval of larotrectinib and entrectinib. Furthermore, 1 CR was excluded because the patient was affected by a hematologic tumor. The results of the included single sources of evidence are described in Table 1.

3.2. Synthesis of Results

Data extracted from the included CR and CS allowed us to create a virtual cohort of 43 patients affected by NTRK gene fusion-positive tumors treated with TRK inhibitors, including 25 adult and 18 pediatric patients (Table 2).

The median age in the overall population was 37 years (range: <1–81 years). The median age for adult patients was 56 years (range: 26–81), while for pediatric patients, it was 4 years (range: <1–14). Furthermore, 19 (44.2%) patients were male (11 adult and 8 pediatric patients) and 21 (48.8%) female (14 adult and 7 pediatric patients). Sex was not reported in 3 cases (7%). In the overall population, the frequencies of tumor types harboring an NTRK gene fusion were soft tissue sarcoma (30.2%), central nervous system (CNS) tumor (27.9%), thyroid tumor (14%), salivary gland tumor (9.3%), lung cancer (4.8%), cervical cancer (2.3%), breast cancer (2.3%), colon cancer (2.3%), ovarian cancer (2.3%),
pancreatic tumor (2.3%), and thymoma (2.3%). Among adult patients, the most frequent tumor types were thyroid tumors (24%), salivary gland tumors (16%), and CNS tumors (16%) while for pediatric patients, they were soft tissue sarcoma (55.6%) and CNS tumors (44.4%). Furthermore, the majority of patients (79.1%) were treated with TRK inhibitors for a metastatic disease. The metastatic sites in the overall population were lungs (38.2%), lymph nodes (38.2%), bone (26.5%), liver (20.6%), pleura (14.7%), soft tissues (14.7%), brain (8.8%), adrenal gland (8.8%), peritoneum (8.8%), kidney (5.9%), leptomeninges (5.9%), pancreas (5.9%), mediastinum (5.9%), and ovary (2.9%). In addition, 38.2% of patients had loco-regional recurrence.

In the overall population, the detected NTRK gene rearrangements involved NTRK1, NTRK2, and NTRK3 in 25.6%, 16.3%, and 51.2% of cases, respectively. However, in 7% of cases, the authors did not report the specific NTRK gene involved. The most common NTRK fusion partners were ETV6 (37.2%), TMP3 (7%), and EML4 (7%). NTRK gene fusions were detected in the primitive tumor or distant metastases’ specimens in 69.7% and 16.3% of cases, respectively. Among the methodologies for NTRK gene fusions’ detection, immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), DNA- or RNA-based NGS assays, and reverse transcription–polymerase chain reaction (RT-PCR) were used in 27.9%, 18.6%, 83.7%, and 0% of cases, respectively. No information was reported in 16.6% of cases on the methodologies used for NTRK gene fusion’s detection. Before receiving an TRK inhibitor, 90.7% of patients were treated with other treatments, particularly, surgery (67.4%), chemotherapy (39.5%), targeted therapies (20.9%), immune checkpoint inhibitors (4.7%), radiotherapy (27.9%), radioactive iodine therapy (9.3%), and chemoradiotherapy (14%).

In terms of treatment, larotrectinib and entrectinib were administered in 81.4% and 16.3% of patients, respectively. Furthermore, in one case (2.3%), the patient was treated with both drugs. TRK inhibitors were used as first- and second-line therapy in 34.9% of cases. In addition, in 16.3% of cases, TRK inhibitors were used as third line and, in 6.9% of cases, they were used in the subsequent lines. The best radiological response to TRK inhibitors was partial response (74.5%), while a complete response was achieved in 20.9% of cases. In contrast, only 2.3% of cases had stable or progressive disease, respectively. Finally, at the time of publication, 72.1% patients were alive with disease, 11.6% died due to progressive disease, and no information was reported for 16.3% of cases.

3.3. Quality Assessment

All the included publications were evaluated with a tool proposed by Murad et al. [18]. The aggregated scores assigned to every CR and CS included in the study are available in Supplementary Material S2.
Table 1. Variables extracted from eligible publications.

| First Author | Journal of Publication (Year) | Type of Evidence | Type of Evidence | Age (Sex) | Tumor Type | Histology | Sites of Metastases | NTRK Gene Fusion | Diagnosis | Previous Treatments | NTRK Inhibitor (Line of Therapy) | Best Radiological Response (Duration of Response) | Outcome |
|--------------|--------------------------------|------------------|------------------|-----------|------------|-----------|---------------------|-----------------|-----------|---------------------|-----------------------------------|-----------------------------------------------|---------|
| Landman et al. [19] | Clin Breast Cancer (2018) | CR               | 37 (F)           | BC         | Secretory breast carcinoma | Bone, lung, lymph nodes, peritoneum, pleura | ETV6-NTRK3 | NGS | Surg-RT | Laro (1) | PR (6 *) | AwD |
| Ziegler et al. [20] | Br J Cancer (2018) | CR               | 3 (F)            | CNS        | High-grade glioma | Loco-regional recurrence | ETV6-NTRK3 | NGS | Surg-ChT-RT | Laro (2) | PR (9 *) | AwD |
| Wong et al. [21] | Pathology (2020) | CS               | 65 (F)           | STS        | Fibrosarcoma | Adrenal gland, kidney, liver, pancreas | ETV6-NTRK3 | FISH-IHC-NGS | Surg-RT | Entre (1) | PR (1 *) | AwD |
| Hochmair et al. [22] | Clin lung cancer (2020) | CR               | 30 (F)           | LC         | Adenocarcinoma | Bone | TPM3-NTRK1 | IHC-NGS | Cht | Laro (2) | PR (4 *) | AwD |
| Alharbi et al. [23] | JCO Precis Oncol (2020) | CR               | 2 (F)            | CNS        | High-grade glioma | Loco-regional recurrence | ETV6-NTRK3 | NGS | Surg | Laro (1) | PR (6 *) | AwD |
| Mayr et al. [24] | J Pers Med (2020) | CS               | 9 (NA)           | STS        | Gliosarcoma | Bone, leptomeninges | EML4-NTRK3 | NGS | Surg-ChT-RT | Entre (3) | PR (5) | DoD |
| Walter et al. [25] | Pediatr Blood Cancer (2020) | CR               | 6 (NA)           | CNS        | Low-Grade Glioma | No distant metastases | NACC2-NTRK | NA | Cht-TargT | Laro (5) | PR (NA) | NA |
| Salame et al. [26] | Cureus (2021) | CR               | 50 (M)           | Thymus     | Thymoma | Pleura | EIF4B-NTRK3 | NGS | Cht | Entre (2) | PR (10 *) | AwD |
| Zhang et al. [27] | BMC Pulm Med (2021) | CR               | 60 (F)           | LC         | Adenocarcinoma | Lung, pleura | NCOR2-NTRK | IHC-NGS | Surg-ICI | Laro (3) | PR (15 *) | AwD |
| Gupta et al. [28] | J Natl Compr Canc Netw (2021) | CR               | 81 (M)           | PC         | Pancreatic acinar cell carcinoma | Liver, lymph nodes | SEL1L-NTRK1 | NGS | Surg-Cht | Laro (2) | PR (13 *) | AwD |
| Percy et al. [29] | Clin Case Rep (2021) | CR               | 30 (M)           | STS        | Spindle cell sarcoma | No distant metastases | SPECC1L-NTRK | IHC-NGS | None | Laro (Neoadj) | PR (8 *) | AwD |
| Munkhdelger et al. [30] | Int J Surg Pathol (2021) | CR               | 72 (F)           | CC         | Basaloid squamous cell carcinoma | Lung | DLG2-NTRK2 | NGS | Surg | Laro (1) | PR (NA) | NA |
| Pircher et al. [31] | Medicine (Baltimore) (2021) | CR               | 63 (M)           | SG         | Carcinoma ex pleomorphic adenoma | Lung, lymph nodes | ZCCHC7-NTRK | NGS | Surg-RT | Laro (1) | SD | AwD |
| Pitoia et al. [32] | Clin Case Rep (2021) | CR               | 56 (F)           | TT         | Papillary | Adrenal gland, bone, brain, liver, lymph nodes, lung, pleura, soft tissue | ETV6-NTRK3 | NGS | RAI-TargT | Laro (3) | CR (11 *) | AwD |
| First Author               | Journal of Publication (Year) | Type of Evidence | Age (Sex) | Tumor Type | Histology | Sites of Metastases | NTRK Gene Fusion | Diagnosis | Previous Treatments | NTRK Inhibitor (Line of Therapy) | Best Radiological Response (Duration of Response) | Outcome |
|---------------------------|-------------------------------|------------------|-----------|------------|-----------|--------------------|------------------|-----------|-------------------|---------------------------------|---------------------------------------------|---------|
| Shepherd et al. [33]      | Oncologist (2021)             | CR               | 26 (M)    | CNS        | Glioblastoma | Loco-regional recurrence | KANK1-NTRK2      | NGS-FISH | CT/RT             | Laro-Entre (2)                  | PR (3.5 ⁵)                              | DoD     |
| Wagner et al. [34]        | Diagn Pathol (2021)           | CR               | 38 (M)    | SG         | Mammary analogue secretory carcinoma | Bone, lungs      | ETV6-NTRK3      | IHC-FISH-NGS | Surg-Cht-CT/RT | Laro (1)                        | PR (8 *)                               | AwD     |
| Boyer et al. [35]         | Neuro Oncol (2021)            | CR               | 53 (M)    | CNS        | High-grade glioma | Loco-regional recurrence | STRN1-NTRK2 | NGS     | Surg-CT/RT         | Laro (2)                        | CR (11 *)                               | AwD     |
| Corral Sánchez et al. [36]| Pediatr Hematol Oncol (2021)  | CR               | <1 (F)    | STS        | Infantile fibrosarcoma | No distant metastases | ETV6-NTRK3 | FISH None | Laro (1)                        | CR (14 *)                               | AwD     |
| Goh et al. [37]           | J Oncol Pharm Pract (2021)    | CR               | 14 (M)    | STS        | Non-rhabdomyosarcoma soft tissue sarcoma | Soft tissues      | DCTN1-NTRK1 | IHC-NGS | ChT-RT-Surg         | Laro (2)                        | PR (6)                                  | DoD     |
| Carter-Febres et al. [38] | Pediatr Hematol Oncol (2021)  | CS               | 2 (F)     | STS        | Undifferentiated embryonal sarcoma | No distant metastases | ETV6-NTRK3 | NGS     | ChT-Surg Laro (Adj) | CR (12 *)                               | AwD     |
| Slomovic et al. [39]      | Pediatr Blood Cancer (2021)   | CR               | <1 (M)    | STS        | Infantile fibrosarcoma | No distant metastases | NACC2-NTRK2 | NGS     | Surg-CT/RT Laro (Adj) | CR (15 *)                               | AwD     |
| Waters et al. [40]        | Pediatr Blood Cancer (2021)   | CR               | 2 (M)     | CNS        | Glioma | Loco-regional recurrence | EML4-NTRK3 | NA     | Surg-ChT Laro (2) | PR (12 *)                               | AwD     |
| Mangum et al. [41]        | JCO Precis Oncol (2021)       | CR               | 6 (M)     | CNS        | Ependymoma | Loco-regional recurrence, leptomeninges | KANK1-NTRK2 | NGS     | Surg-RT Laro (1) | PR (10 *)                               | AwD     |
| Endo et al. [42]          | Mol Clin Oncol (2022)         | CR               | 56 (F)    | OC         | High-Grade Serous Carcinoma | Lymph nodes, peritoneum, pleura, liver | TPM3-NTRK1 | NGS     | ChT-Surg-TargT Entre (6) | PD                                  | DoD     |
| Ernst et al. [43]         | Curr Oncol (2022)             | CR               | 59 (M)    | SG         | Mammary analogue secretory carcinoma | Loco-regional recurrence, lung | ETV6-NTRK3 | FISH-NGS | Surg Entre (1) | PR (49 *)                               | AwD     |
| Recine et al. [44]        | Front Oncol (2022)            | CR               | 14 (M)    | STS        | Dermatofibrosarcoma | Bone, kidney, liver, lung, soft tissue | TPM4-NTRK1 | NGS     | Surg-RT-TargT Laro (2) | PR (23 *)                               | AwD     |
| First Author | Journal of Publication (Year) | Type of Evidence | Age (Sex) | Tumor Type | Histology | Sites of Metastases | NTRK Gene Fusion | Diagnosis | Previous Treatments | NTRK Inhibitor (Line of Therapy) | Best Radiological Response (Duration of Response) | Outcome |
|--------------|------------------------------|-----------------|-----------|------------|-----------|------------------|-----------------|-----------|---------------------|----------------------------------|-----------------------------------------------|---------|
| Bill et al. [45] | Cancer Rep (Hoboken) (2022) | CR              | 56 (F)   | SG         | Mammary analogue secretory carcinoma | Lymph nodes | ETV6-NTRK3 | IHC-NGS | Surg-CT/RT | Laro (2)                                   | CR (13 *)                                      | AwD     |
| Bargas et al. [46] | Eur J Endocrinol (2022) | CR              | 50 (F)   | TT         | Papillary | Lung, ovary, mediastinum, lymph node | SQSTM1-NTRK1 | NGS-FISH | Surg-RAI-TargT | Laro (3)                                   | PR (18 *)                                      | AwD     |
| Kasi et al. [47] | Cureus (2022) | CR              | 43 (F)   | CoC        | Adenocarcinoma | Lymph nodes, peritoneum | TPR-NTRK1 | NGS-IHC | Surg-ICI | Laro (2)                                   | PR (3 *)                                       | AwD     |
| Saliba et al. [48] | Head Neck Pathol (2022) | CR              | 49 (M)   | TT         | Secretory carcinoma | Loco-regional recurrence, lymph nodes, lung | ETV6-NTRK3 | NGS | Surg | Laro (1)                                   | PR (18)                                      | DoD     |
| Lapeña et al. [49] | European J Pediatr Surg Rep (2022) | CS              | <1 (F)   | STS        | Infantile fibrosarcoma | No distant metastases | ETV6-NTRK3 | NA | None | Laro (1)                                   | CR (14 *)                                      | AwD     |
| Groussin et al. [50] | Thyroid (2022) | CS              | 65 (F)   | TT         | Papillary | Bone, liver, lymph nodes, lung | EML4-NTRK3 | NGS | RAI-TargT | Laro (3)                                   | PR (NA)                                       | NA      |
| Groussin et al. [50] | Thyroid (2022) | CS              | 48 (F)   | TT         | Papillary | Lymph nodes, lung | ETV6-NTRK3 | NGS | RAI-TargT | Laro (3)                                   | PR (NA)                                       | NA      |
| Groussin et al. [50] | Thyroid (2022) | CS              | 70 (F)   | TT         | Oxyphilic cell papillary | Brain, bone, lymph nodes, liver, lung, pancreas, soft Tissue | TPM3-NTRK1 | NGS | Surg | Laro (1)                                   | PR (NA)                                       | NA      |
| Grogan et al. [51] | Neurooncol Adv (2022) | CR              | 67 (M)   | CNS        | Glioblastoma | Loco-regional recurrence | BCR-NTRK2 | NGS | Surg-RT | Entre (1)                                | PR (15)                                       | NA      |
| Kobayashi et al. [52] | Genes Chromosomes Cancer (2022) | CR              | 57 (M)   | STS        | Malignant peripheral nerve sheath tumors | Lymph nodes, lung | SNRNP70-NTRK3 | FISH-IHC-NGS | Surg-RT-ChT-TargT | Entre (4)                                 | PR (11)                                       | NA      |
| König et al. [53] | Pharmacology (2022) | CR              | 80 (F)   | CNS        | High-grade glioma | No distant metastases | ARHGEF7-NTRK3 | NGS | RT | Laro (1)                                   | PR (4.5)                                      | AwD     |
| Olsen et al. [54] | J Pediatr Hematol Oncol (2022) | CR              | 6 (F)    | STS        | High-grade spindle cell sarcoma | Bone | NTRK3 gene rearrangement | IHC-FISH | ChT-RT | Laro (3)                                   | PR (22)                                      | AwD     |
| First Author | Journal of Publication (Year) | Type of Evidence | Age (Sex) | Tumor Type | Histology | Sites of Metastases | NTRK Gene Fusion | Diagnosis | Previous Treatments | NTRK Inhibitor (Line of Therapy) | Best Radiological Response (Duration of Response) | Outcome |
|--------------|-------------------------------|------------------|-----------|------------|-----------|--------------------|-----------------|-----------|-------------------|---------------------------------|-----------------------------------------------|---------|
| Mançano et al. [55] | Pathobiology (2022) | CR | <1 (M) | STS | Gliosarcoma | Loco-regional recurrence | TPR-NTRK1 | FISH-NGS | Surg-ChT | Laro (2) | PR (8 *) | AwD |
| Di Ruscio et al. [56] | Diagnostics (2022) | CS | 1 (NA) | CNS | High-grade glioma | Loco-regional recurrence | ETV6-NTRK3 | NGS | Surg-ChT-TargT | Laro (2) | CR (24 *) | AwD |
| 1 (F) | CNS | High-grade glioma | Loco-regional recurrence | MEF2D-NTRK1 | NGS | Surg-ChT | Laro (2) | PR (4 *) | AwD |

* Response was ongoing at the time of publication. After 8 months of larotrectinib the patient underwent radical surgery. The duration of response is related to larotrectinib. After 3 months of larotrectinib, the patient underwent radical surgery and, subsequently, the treatment was continued to complete a total of 6 months of peri-operative therapy. Abbreviations: Adjuvant (Adj); Alive with Disease (AwD); Breast Cancer (BC); Case Report (CR); Case Series (CS); Central Nervous System (CNS); Cervical Cancer (CC); Chemotherapy (ChT); Chemoradiotherapy (CT/RT); Colon Cancer (CoC); Complete Response (CR); Died of Disease (DoD); Disks Large homolog 2 (DLC2); Dynactin Subunit 1 (DCTN1); Echinoderm Microtubule Associated Protein-Like 4 (EML4); Entrectinib (Entre); ETS Variant Transcription Factor 6 (ETV6); Eukaryotic translation initiation factor 4B (EIF4B); Female (F); Fluorescence in situ hybridization (FISH); Follow-Up (FU); Immune Checkpoint Inhibitor (ICI); Immunohistochemistry (IHC); Infantile Fibrosarcoma (IFS); KN Motif and Ankyrin Repeat Domains 1 (KANK1); Larotrectinib (Laro); Lung Cancer (LC); Male (M); Malignant peripheral nerve sheath tumors; NACC Family Member 2 (NACC); Next-Generation Sequencing (NGS); Not Applicable (NA); Nuclear Receptor Corepressor 2 (NCOR2); Neoadjuvant (Neoadj); Ovarian Cancer (OC); Pancreas Cancer (PC); Partial Response (PR); Progressive Disease (PD); Radioactive Iodine (RAI); Radiotherapy (RT); Rho Guanine Nucleotide Exchange Factor 7 (ARHGEP7); Rho/Rac guanine nucleotide exchange factor 2 (ARHGEP2); Salivary Gland Tumor (SG); SEL1L adaptor subunit of ERAD E3 ubiquitin ligase (SEL1L); Sequestosome 1 (SQSTM1); Small Nuclear Ribonucleoprotein U1 Subunit 70 (SNRP70); Soft Tissue Sarcoma (STS); Sperm Antigen with Calponin Homology and Coiled-Coil Domains 1 Like (SPECC1L); Stable Disease (SD); Strictosidine synthase (STR1); Surgery (Surg); Translocated Promoter Region (TPR); Targeted Therapy (TargT); Thyroid Tumor (TT); Tropomyosin 3 (TMP3); Tropomyosin 4 (TMP4); Whole-Exome Sequencing (WES); Zinc Finger CCHC-Type Containing 7 (ZCCHC7).
### Table 2. Results of quantitative analysis of data extracted by included publications.

| Included Publications | Sites of Metastases—n (%) | Diagnosis—n (%) |† |
|-----------------------|---------------------------|----------------|---|
| Number of CR          | 32                        | LR recurrence  | 13 (38.2%) | NGS | 36 (83.7%) |
| Number of CS          | 6                         | Lymph nodes    | 13 (38.2%) | IHC | 12 (27.9%) |
| Year of publication   | (Range)                   |                |            |     |            |
|                       | 2018–2022                 |                |            |     |            |
| Demographics—n (%)    |                           |                |            |     |            |
| Number of patients    | 43                        |                |            |     |            |
| Median Age            | 37 (<1–81)                |                |            |     |            |
| Adult–Children        | 25 (58.1%)–18 (41.9%)     |                |            |     |            |
| Male–Female *         | 19 (44.2%)–21 (48.8%)     |                |            |     |            |
| Tumor types—n (%)     |                           |                |            |     |            |
| Soft tissue sarcoma   | 13 (30.2%)                | Kidney         | 2 (5.9%)   |     |            |
| CNS tumors            | 12 (27.9%)                | Leptomeninges  | 2 (5.9%)   |     |            |
| Thyroid tumors        | 6 (14%)                   | Pancreas       | 2 (5.9%)   |     |            |
| Salivary gland tumors | 4 (9.3%)                  | Ovarian        | 1 (2.9%)   |     |            |
| Lung tumor            | 2 (4.8%)                  | NTRK gene fusion partner—n (%) |      |     |            |
| Breast cancer         | 1 (2.3%)                  | ETV6           | 16 (37.2%) | Partial response | 32 (74.5%) |
| Colon cancer          | 1 (2.3%)                  | TMP3           | 3 (7%)     | Complete response | 9 (20.9%) |
| Ovarian cancer        | 1 (2.3%)                  | EML4           | 3 (7%)     | Stable disease    | 1 (2.3%) |
| Pancreatic tumor      | 1 (2.3%)                  |                |            |     |            |
| Thymus                | 1 (2.3%)                  |                |            |     |            |
| Cervix cancer         | 1 (2.3%)                  |                |            |     |            |
| Site of NTRK gene fusion detection—n (%) |       | NTRK [Line of therapy]—n (%) |      |
| Stage—n (%)           |                           |                |            |     |            |
| Metastatic            | 34 (79.1%)                | Metastasis     | 7 (16.3%)  | Alive with disease | 31 (72.1%) |
| Alive with disease    |                           |                |            |     |            |
| Dead of disease       |                           |                |            |     |            |

* Not reported in 3 cases (7%). ** Most frequent NTRK gene fusion partner. † Not reported in 6 cases (14%).

4. Discussion

4.1. Summary of Evidence

In recent years, the advances in molecular diagnosis have led to a significant change in how cancer patients are treated, shifting from a “one size fits all” therapeutic paradigm toward a “precision medicine” approach with the development of new agents targeting specific genomic abnormalities [4–58]. This revolution has been witnessed by the progressive discovery of an increasing number of actionable molecular alterations, gaining the chance of improving cancer patients’ survival with biomarker-driven drugs [1]. Nowadays, several “agnostic therapies” have been approved for patients harboring specific genomic alterations, based on the possibility of administering targeted therapies across different tumor histologies and regardless of the tumor site of origin [59].

In recent years, NTRK gene fusion has represented one of the most groundbreaking discoveries among the biomarkers targeted by agnostic therapies. The family of NTRK genes (NTRK1, NTRK2, NTRK3) encodes for TrkA, TrkB, and TrkC receptors, respectively [11]. They are composed of an intracellular domain, a transmembrane region, and an extracellular domain for ligand binding [60]. Beyond their physiological involvement in...
the nervous system’s development, the constitutive activation of Trk receptors mediated by the occurrence of NTRK gene fusions leads to the uncontrolled growth of cancer cells [11]. Particularly, the interaction between TRK receptors and their ligands triggers the activation of signal transduction pathways implicated in tumorigenesis, including Ras/Mitogen activated protein kinase (MAPK), the phosphatidylinositol-3-kinase (PI3K)/Akt, and the mammalian target of rapamycin (mTOR) pathways (Figure 3) [61].

![Figure 3. TRK receptors’ intracellular signaling pathway. The interaction between the receptor and the ligand activates crosstalk between multiple intracellular molecular cascades. Abbreviations: protein kinase B (AKT); Diacylglycerol (DAG); Extracellular signal-regulated kinase (ERK-1); GRB2-Associated Binding Protein-1 (GAB-1); Growth Factor Receptor-Bound Protein-2 (GRB-2); Inositol trisphosphate (IP-3); Mitogen-activated protein kinase (MEK); Mammalian Target of Rapamycin (mTOR); Nuclear Factor Kinase-β (NF-Kβ); 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK-1); Protein Kinase C (PKC); Phospholipase C-γ (PLC-γ); Rapidly Accelerated Fibrosarcoma (RAF); Rat Sarcoma virus (RAS); Son of Sevenless (SOS). Created with BioRender.com.](image-url)

In 2013, Vaishnavi et al. described, for the first time, an NTRK1 gene rearrangement in a cohort of patients affected by non-small cell lung cancer [62]. Since then, several studies aiming to describe the genomic landscape and the prevalence of NTRK gene fusions in solid tumors have been published. In 2019, Rosen et al. reported the analysis of genomic and clinical data about NTRK gene-positive tumors identified among more than 26,000 prospectively sequenced patients. Seventy-six cases (0.28%) with confirmed NTRK fusions were identified, mainly represented by salivary gland cancer, soft tissue sarcomas, and thyroid cancers [63]. In 2020, Forsythe et al. reported the results of a systematic review and meta-analysis aiming at describing the NTRK gene fusion incidence among available studies published from 1987 to 2020. The authors showed that rare tumors, such as secretory breast cancer, infantile fibrosarcoma, secretory salivary gland cancer, papillary thyroid carcinoma (pediatric), and congenital mesoblastic nephroma, were characterized by the highest NTRK gene fusion frequencies (from 10 to 92.8%) [64]. In 2021, Westphalen et al. reported the results of a retrospective study which aimed to evaluate the genomic landscape and prevalence of NTRK gene fusions in a large real-world database of comprehensive genomic profiling data (FoundationCORE). Among more than 295,000 analyzed cancer cases, salivary gland cancers (2.43%), soft tissue sarcomas (1.27%), and thyroid cancers (1.25%) were the most common tumor types harboring NTRK gene fusions [65].

From a diagnostic point of view, several assays have been developed to accurately identify patients harboring an NTRK gene fusion, including IHC, FISH, RT-PCR, and...
DNA- or RNA-based NGS. However, the advantages and disadvantages of each diagnostic modality must be weighed when evaluating the tissue specimen required for NTRK gene fusions analysis [66]. To this aim, the European Society of Medical Oncology Translational Research and Precision Medicine Working Group published recommendations for a rational approach for detecting NTRK gene fusions based on the prevalence of these alterations among different tumor histotypes [67]. In tumors with highly frequent NTRK fusions, the best methodologies to use as confirmatory tests are FISH, RT-PCR, or targeted RNA NGS assays. Differently, in tumors where NTRK fusions are recognized not to be highly prevalent, NGS targeted panels (DNA- or RNA-based) are the recommended tests of choice. In case of an NTRK gene fusion detection by the use of NGS-based assays, a further confirmatory test with IHC is recommended [67]. Alternatively, if a sequencing platform is not available, IHC may be used as a screening tool, followed by an NGS targeted panel, in case of a positive result [67].

Nowadays, two targeted agents are available for patients harboring NTRK gene fusions: larotrectinib and entrectinib. The former was granted accelerated approval by the FDA in 2018 [9] after Drilon et al. published a prespecified combined analysis of three clinical trials evaluating the activity of larotrectinib in patients with locally advanced or metastatic NTRK fusion-positive solid tumors. The studies involved in the analysis were a phase 1 trial on adults (LOXO-TRK-14001), a phase 1–2 trial on children (SCOUT), and a phase 2 “basket” trial involving adolescents and adults (NAVIGATE). Among the 55 patients enrolled, the overall response rate was 75% (95% CI, 61–85%) after a median follow-up of 9.4 months [14]. After two years, Hong et al. reported the results of an expanded pooled efficacy analysis on 159 patients enrolled across the same 3 clinical trials. Although only 153 patients were evaluable for response, the objective response rate was 79% (95% CI, 72–85%) after a median follow-up of 11.1 months. In total, 24 (16%) patients achieved a complete response, and the median progression-free survival was 28.3 months (95% CI, 22.1—not reached) [68]. Recently, Drilon et al. updated the previous results by publishing the efficacy analysis on 244 patients. The objective response rate was 69% (95% CI, 63–75%), with a complete response rate of 26%. The median progression-free survival was 29.4 months (95% CI, 19.3–34.3 months) after a median follow-up of 29.3 months [69].

In contrast, entrectinib was granted accelerated approval by the FDA in 2019 [10] after Doebele et al. published a pooled analysis of three clinical trials that investigated the activity of entrectinib in locally advanced or metastatic cancer patients harboring an NTRK gene fusion. The studies involved in the analysis were two phase I trials (ALKA-372–001 and STARTTRK-1) and one phase II trial (STARTTRK-2). The objective response rate was 57% (95% CI, 43.2–70.8%) among the enrolled 54 patients, after a median follow up of 12.9 months. The complete response rate was 7% and the median duration of response was 10 months (95% CI, 7.1–NE) [15].

Overall, the population included in the above-mentioned clinical trials was composed of patients affected by different tumor histologies harboring an NTRK gene fusion. The most frequent tumor histotypes were soft tissue sarcomas, lung, salivary gland, and thyroid cancer. In contrast, gastrointestinal (except for colorectal cancer), genito-urinary, and gynecological malignancies were under or not-represented [14,15]. However, since the rapid evolution of precision medicine has determined a reduction in the cost of molecular profiling, NGS assays have become increasingly available in clinical practice. Accordingly, health care professionals are more likely to face the detection of NTRK gene fusions in patients affected by tumor histologies under or not represented in the clinical trial, with the consequent lack of data on the efficacy of TRK inhibitors. Therefore, we systematically reviewed the available literature for CS and CR on NTRK gene fusion-positive tumors treated with TRK inhibitors.

The publication of CR and CS has often played an essential role in advancing medical knowledge on rare conditions [18–70]. In this context, the creation of a virtual cohort of patients from CR and CS on NTRK gene fusion-positive solid tumors treated with TRK inhibitors has a double value. On the one hand, it provides health care professionals with a
single source of evidence that is easy to access and summarizes data derived from multiple clinical experiences. On the other hand, the choice to exclude both CR and CS on patients enrolled in the clinical trials lends this virtual cohort of patients the opportunity to be compared with populations enrolled in the clinical trials \cite{14,15}. Nevertheless, since the intrinsic bias of both CR and CS is related to their nature and the inclination to publish more reports of positive rather than negative responses to treatments, it is essential to be cautious in the extrapolation of emerging data to clinical practice \cite{18}.

The data obtained from this patients’ cohort appear in line with those available in the current literature. Indeed, patients were affected by the most frequent tumor types as those reported in the clinical trials that led to the approval of larotrectinib and entrectinib \cite{14,15}, such as soft tissue sarcoma, thyroid, and salivary gland tumors (Table 3). In our opinion, a reasonable explanation for these similar results relies on the different frequencies of NTRK gene fusions among different tumor histotypes, as reported in the above-mentioned multiple retrospective studies \cite{63–65}. Although the NTRK gene fusions are rare genomic abnormalities, they can be detected with high frequencies in some rare cancers (secretory breast carcinoma, mammary analogue secretory carcinoma, congenital infantile fibrosarcoma) and with lower frequencies in a range of common adult patients’ cancers \cite{13}.

In our cohort, we found a higher prevalence of patients affected by primary CNS tumors (27.9\%) compared to those reported in the abovementioned clinical trials’ combined analyses. Nowadays, these patients lack effective therapies \cite{71} and, thus, our results confirm the indication of the current guidelines that encourage performing molecular testing for NTRK gene fusion in CNS tumors \cite{72}. However, it is important to cautiously interpret the extremely positive outcomes reported by the patients included in our cohort due to the “publication bias” related to CR and CS. In this direction, a recently published post-hoc analysis of two clinical trials that led to the approval of larotrectinib showed an objective response rate of 30\% (95\% CI, 16–49) with a 24-week disease control rate of 73\% (95\% CI: 54–87) for primary CNS tumors \cite{73}. Nevertheless, considering the reported benefit of administering TRK inhibitors in this subgroup of patients and the data available in the literature, the detection of an NTRK gene fusion in CNS tumors may represent a “game-changer” in treating those malignancies.

Finally, our results confirm how TRK inhibitors represent a significant therapeutic strategy for metastatic cancer patients harboring an NTRK gene fusion, and, thus, all the cancer patients harboring this molecular alteration should be evaluated for specific inhibitors \cite{74}. Although these drugs are generally administered as a single-agent treatment in the metastatic setting, we found a cervical cancer patient treated with the combination of chemotherapy plus larotrectinib \cite{30} and two pediatric patients treated with “adjuvant” maintenance larotrectinib after definitive surgical resection of a kidney sarcoma and anaplastic astrocytoma \cite{38}. These reports are interesting because they focus on new potential strategies of TRK inhibitors’ administration in terms of clinical setting (adjuvant vs. metastatic disease) and combinations (single agent vs. combined treatment). In our opinion, considering the importance of maximizing the benefit of these drugs, we believe that these strategies should be further assessed in the near future. In parallel, it is essential to provide guidelines to help healthcare professionals determine the best time to administer these anticancer agents. Recently, a Belgian expert consensus for the tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib has been published \cite{75}. The authors distinguished three categories of patients affected by NTRK gene fusion-driven solid tumors: (i) those affected by advanced solid tumors with non-satisfactory standard-of-care (SoC) therapies, (ii) those with advanced solid tumors with satisfactory SoC therapies, and (iii) those affected by locally advanced tumors \cite{75}. For the first group, it was suggested to consider the use of larotrectinib as a first-line treatment, considering the high unmet medical need for these patients. Concerning the second group, the authors suggested larotrectinib as a consideration for second or later treatment line (after failure of SoC). For the last group, larotrectinib should be considered as a neoadjuvant therapy \cite{75}.
Table 3. Frequencies of tumor types in the clinical trials that led to the approval of larotrectinib and entrectinib and in our virtual cohort of patients.

| Tumor Types                    | Larotrectinib (LOXO-TRK-14001; SCOUT; NAVIGATE) [68] | Entrectinib (STARTRK-1; STARTRK-2; ALKA-372-001) [15] | Larotrectinib + Entrectinib (Virtual Cohort of CR and CS) [49–56] |
|--------------------------------|------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------|
| Appendix cancer                | 1 (<1%)                                              | -                                                   | -                                                              |
| Bone sarcoma                   | 2 (1%)                                               | -                                                   | -                                                              |
| Breast cancer                  | 5 (3%)                                               | 6 (11%)                                             | 1 (2.3%)                                                       |
| Congenital mesoblastic nephroma| 1 (<1%)                                              | -                                                   | -                                                              |
| Cholangiocarcinoma             | 2 (1%)                                               | 1 (2%)                                              | -                                                              |
| Colorectal cancer              | 8 (5%)*                                              | 4 (7%)*                                             | 1 (2.3%)*                                                      |
| Cervical cancer                | -                                                   | -                                                   | 1 (2.3%)                                                       |
| Endometrial cancer             | -                                                   | -                                                   | -                                                              |
| Central nervous system tumor   | -                                                   | -                                                   | 12 (27.9%)                                                     |
| Hepatocellular tumor           | 1 (<1%)                                              | -                                                   | -                                                              |
| Lung cancer                    | 12 (8%)                                              | 10 (19%) **                                         | 2 (4.8%)                                                       |
| Melanoma                       | 7 (4%)                                               | -                                                   | -                                                              |
| Neuroendocrine tumor           | -                                                   | 3 (6%)                                              | -                                                              |
| Ovarian cancer                 | -                                                   | 1 (2%)                                              | 1 (2.3%)                                                       |
| Pancreas cancer                | 2 (1%)                                               | 3 (6%)                                              | 1 (2.3%)                                                       |
| Prostate cancer                | 1 (<1%)                                              | -                                                   | -                                                              |
| Salivary gland tumor           | 21 (13%)                                             | 7 (13%)                                             | 4 (9.3%)                                                       |
| Soft tissue sarcoma            | 69 (44%)                                             | 13 (24%)                                             | 13 (30.2%)                                                     |
| Thyroid cancer                 | -                                                   | -                                                   | 1 (2.3%)                                                       |
| Unknown primary                | 1 (<1%)                                              | -                                                   | -                                                              |

* Only colon cancer. ** Only non-small cell lung cancer histology. † Only mammary analogue secretory carcinoma histology. § Including cervical adenosarcoma, dedifferentiated chondrosarcoma, endometrial stromal sarcoma, follicular dendritic cell sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and sarcoma not otherwise specified. # Including infantile fibrosarcoma, gastrointestinal stromal tumor, and other.

4.2. Future Perspectives

We believe that the creation of prospective, international patients’ registries would represent an essential tool to acquire “real-word” data on the efficacy of TRK inhibitors among NTRK gene fusion positive tumors, including histotypes under or not represented in previous clinical trials. Currently, two ongoing studies aim to collect data prospectively in these patients: the REALTRK registry [76] and the TRacKING registry [77]. The former aims to analyze the treatment reality and outcomes of NTRK gene fusion-positive patients treated with TRK inhibitors until at least 36 months after their inclusion in the study [76]. The latter aims to study the real-life management of patients with rare actionable fusions, including those harboring an NTRK gene fusion [77].

4.3. Limitations

The present systematic review has some limitations. Firstly, a limited number of CR and CS lacked relevant clinical data and were at high risk of several biases. Secondly, we did not include CS reporting on aggregate patients’ data instead of individual data. Unfortunately, these limitations are common in studies that evaluate CR and CS [78,79], but they were considered before designing the protocol. In addition, the search strategy was designed to be extensive, and both the data extraction and selection were performed with a “two-stage process” to minimize bias.

5. Conclusions

The results of our systematic review confirmed the efficacy of TRK inhibitors in cancer patients harboring an NTRK gene fusion. Although the patients of our virtual cohort were mainly affected by the most frequently diagnosed tumor histologies in patients enrolled in the available clinical trials on TRK inhibitors, we reported a higher prevalence of CNS tumors, confirming the benefit of these agents even in this subgroup of patients. Large, multi-institutional registries are needed to provide more information about the efficacy of TRK inhibitors in cancer patients affected by under or not represented histologies included in the clinical trial that led to the approval of entrectinib and larotrectinib.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12111819/s1, PRISMA 2020 checklist (Supplementary Material S1); Risk of bias assessment for included publications (Supplementary Material S2). Ref. [80] has been cited in Supplementary Materials.

Author Contributions: Conceptualization, G.M.I. and F.T.; methodology, G.M.I.; data curation, G.M.I., S.R. and F.T.; formal analysis, R.R.; writing—original draft preparation, G.M.I., S.G., S.S., M.C. and B.C.; writing—review and editing, S.R., M.R. and F.T.; visualization, R.R.; supervision, M.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Tarantino, P.; Mazzarella, L.; Marra, A.; Trapani, D.; Curigliano, G. The Evolving Paradigm of Biomarker Actionability: Histology-Agnosticism as a Spectrum, Rather than a Binary Quality. *Cancer Treat. Rev.* 2021, 94, 102169. [CrossRef] [PubMed]
2. Tsimberidou, A.M.; Fountzilas, E.; Nikanjam, M.; Kurzrock, R. Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm. *Cancer Treat. Rev.* 2020, 86, 102019. [CrossRef] [PubMed]
3. Hierro, C.; Matos, I.; Martin-Liberal, J.; Ochoa de Olza, M.; Garralda, E. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? *Clin. Cancer Res.* 2019, 25, 3210–3219. [CrossRef] [PubMed]
4. Pestana, R.C.; Sen, S.; Hobbs, B.P.; Hong, D.S. Histology-Agnostic Drug Development-Considering Issues beyond the Tissue. *Nat. Rev. Clin. Oncol.* 2020, 17, 555–568. [CrossRef]
5. FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (accessed on 28 September 2022).
6. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors. Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (accessed on 28 September 2022).
7. FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Advanced Solid Tumors. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors (accessed on 28 September 2022).
8. FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grantsaccelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid (accessed on 28 September 2022).
9. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions. Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions (accessed on 28 September 2022).
10. FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC. Available online: https://www.fda.gov/drugs/resourcesinformation-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (accessed on 28 September 2022).
11. Gatalica, Z.; Xiu, J.; Swensen, J.; Vranic, S. Molecular Characterization of Cancers with NTRK Gene Fusions. *Mod. Pathol.* 2019, 32, 147–153. [CrossRef]
12. Solomon, J.P.; Benayed, R.; Hechtman, J.F.; Ladanyi, M. Identifying Patients with NTRK Fusion Cancer. *Ann. Oncol.* 2019, 30, viii16–viii22. [CrossRef]
13. Cocco, E.; Scaltriti, M.; Drilon, A. NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy. *Nat. Rev. Clin. Oncol.* 2018, 15, 731–747. [CrossRef]
14. Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N. Engl. J. Med.* 2018, 378, 731–739. [CrossRef]
15. Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D.; et al. Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials. *Lancet Oncol.* 2020, 21, 271–282. [CrossRef]
16. Malone, E.R.; Oliva, M.; Sabatini, P.J.B.; Stockley, T.L.; Siu, L.L. Molecular Profiling for Precision Cancer Therapies. *Genome Med.* 2020, 12, 8. [CrossRef]
39. Slomovic, A.; Amaral, T.; Lobko, I.; Siegel, D.N.; Goldfisher, R.; Kessel, R.; Levy, C.F. Comment on: A Newborn with a Large NTRK Fusion Positive Infantile Fibrosarcoma Successfully Treated with Larotrectinib. *Pediatr. Blood Cancer* 2021, 68, e28953. [CrossRef] [PubMed]

40. Waters, T.W.; Moore, S.A.; Sato, Y.; Diouhy, B.J.; Sato, M. Refractory Infantile High-Grade Glioma Containing TRK-Fusion Responds to Larotrectinib. *Pediatr. Blood Cancer* 2021, 68, e28868. [CrossRef]

41. Mangum, R.; Reuther, J.; Bertrand, K.C.; Chandra, M.O.; Kuikre, M.K.; Paulino, A.C.; Muzny, D.; Hu, J.; Gibbs, R.A.; Curry, D.J.; et al. Durable Response to Larotrectinib in a Child with Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. *JCO Precis. Oncol.* 2021, 5, PO.20.00375. [CrossRef] [PubMed]

42. Endo, Y.; Watanabe, T.; Saito, M.; Saito, K.; Suzuki, R.; Sano, H.; Natori, Y.; Sasaki, E.; Ueda, M.; Kamo, N.; et al. A Rare Case of Recurrent Ovarian Cancer with TPSM-NTRK1 Gene Rearrangement: A Case Report. *Mol. Clin. Oncol.* 2022, 16, 90. [CrossRef]

43. Ernst, M.S.; Lyons, J.T.; Hrycza, M.D.; Chandarana, S.P.; Hao, D. TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report. *Curr. Oncol.* 2022, 29, 3933–3939. [CrossRef] [PubMed]

44. Recine, F.; De Vita, A.; Fausti, V.; Pieri, F.; Bongiovanni, A.; Franchini, E.; Casadei, R.; Falasconi, M.C.; Oboldi, D.; Matteucci, F.; et al. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case with Bone and Visceral Metastases Treated with Targeted Therapy. *Front. Oncol.* 2021, 11, 740676. [CrossRef] [PubMed]

45. Bill, R.; Deschler, D.G.; Pittet, M.J.; Pai, S.I.; Sadow, P.M.; Park, J.C. Diagnostic Challenges and Successful Organ-Preserving Therapy in a Case of Secretory Carcinoma of Minor Salivary Glands. *Cancer Res. (Hoboken)* 2022, 5, e491. [CrossRef]

46. Bargas, S.; Mc Leer, A.; Mondet, J.; Chabre, O.; Laramas, M. An Impressive Response with Larotrectinib in a Patient with a Papillary Thyroid Carcinoma Harboring an SQSTM1-NTRK1 Fusion. *Eur. J. Endocrinol.* 2022, 186, E5–K8. [CrossRef]

47. Kasi, F.M.; Afghan, M.K.; Bellizzi, A.M.; Chan, C.H. Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer after Progression on Immunotherapy. *Cureus* 2022, 14, e26648. [CrossRef]

48. Saliba, M.; Mohanty, A.S.; Ho, A.L.; Drilon, A.; Dogan, S. Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. *Head Neck Pathol.* 2022, 16, 612–620. [CrossRef] [PubMed]

49. Lapeña, L.M.; Caldas, M.C.S.; Ramírez-González, V.; Marín-Manzano, E.; Perez-Martínez, A.; Lopez-Gutierrez, J.C. Larotrectinib as an Effectively Therapeutic Option in Congenital Infantile Fibrosarcoma: Report of Two Cases. *Eur. J. Pediatr. Surg. Rep.* 2022, 10, e76–e79. [CrossRef] [PubMed]

50. Groussin, L.; Theodon, H.; Bessiene, L.; Bricaire, L.; Bonnet-Serrano, F.; Cochand-Priollet, B.; Leroy, K.; Garinet, S.; Pasmant, E.; Zerbib, J.; et al. Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. *Thyroid* 2022, 32, 594–598. [CrossRef] [PubMed]

51. Grogan, P.T.; Deming, D.A.; Helligker, J.; Ruszkiewicz, T.; Baskaya, M.K.; Howard, S.P.; Robins, H.I. Entrectinib Demonstrates Prolonged Efficacy in an Adult Case of Radiation-Refractory NTRK Fusion Glioblastoma. *Neurooncol. Adv.* 2022, 4, vdac046. [CrossRef]

52. Kobayashi, H.; Makise, N.; Shinozaki-Ushiku, A.; Zhang, L.; Ishibashi, Y.; Ikegami, M.; Tsuda, Y.; Koshaka, S.; Ushiki, T.; Oda, K.; et al. Dramatic Response to Entrectinib in a Patient with Malignant Peripheral Nerve Sheath Tumor Harboring Novel SNRNP70-NTRK3 Fusion Gene. *Genes Chromosom. Cancer* 2022. [CrossRef]

53. König, D.; Hench, J.; Frank, S.; Dima, L.; Bratic Hench, I.; Läubli, H. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. *Pharmacology* 2022, 107, 433–438. [CrossRef]

54. Olsen, M.R.; Denu, R.A.; Lyon, J.B.; Gulliver, J.M.; Capitini, C.M.; DeSantes, K.B. Undifferentiated and Unresectable Sarcoma with NTRK3-Fusion in a Pediatric Patient Treated with Larotrectinib and Proton Beam Radiotherapy. *J. Pediatr. Hematol. Oncol.* 2022, 5, PO.20.00375. [CrossRef] [PubMed]

55. Mañcano, B.M.; Dos Reis, M.B.; Moreno, D.A.; de Paula, F.E.; de Almeida Junior, C.C.; Cavalcante, C.E.B.; Zanon, M.F.; Santana, I.V.V.; Matsushita, M.; de, M.; et al. A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib. *Pathobiology* 2022, 89, 178–185. [CrossRef]

56. Di Ruscio, V.; Carai, A.; Del Baldo, G.; Vincì, M.; Cavocchi, A.; Miele, E.; Rossi, S.; Antonelli, M.; Barresi, S.; Caluo, M.; et al. Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience. *Diagnostics* 2022, 12, 372. [CrossRef]

57. Kurozumi, K.; Fujii, K.; Washio, K.; Ishida, J.; Otani, Y.; Sudo, T.; Tahara, M.; Ichimura, K.; Ennishi, D.; Date, I. Response to Entrectinib in a Malignant Glioneuronal Tumor with ARHGEF2-NTRK Fusion. *Neurooncol. Adv.* 2022, 4, vdac094. [CrossRef]

58. Iannantuono, G.M.; Torino, F.; Rosenfeld, R.; Guarriero, S.; Carlucci, M.; Spanga, S.; Capotondi, B.; Riondino, S.; Roselli, M. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Int. J. Mol. Sci.* 2022, 23, 8535. [CrossRef] [PubMed]

59. Looney, A.-M.; Nawaz, K.; Webster, R.M. Tumour-Agnostic Therapies. *Nat. Rev. Drug Discov.* 2020, 19, 383–384. [CrossRef] [PubMed]

60. Amato, A.; Sartore-Bianchi, A.; Siena, S. NTRK Gene Fusions as Novel Targets of Cancer Therapy across Multiple Tumour Types. *ESMO Open* 2016, 1, e000023. [CrossRef] [PubMed]

61. Liu, F.; Wei, Y.; Zhang, H.; Jiang, J.; Zhang, P.; Chu, Q. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnostics, Therapy, and TRK Inhibitor Resistance. *Front. Oncol.* 2022, 12, 864666. [CrossRef]

62. Vaishnavi, A.; Capelletti, M.; Le, A.T.; Kakoo, S.; Butaney, M.; Ercan, D.; Mahale, S.; Davies, K.D.; Aisner, D.L.; Pilling, A.B.; et al. Oncogenic and Drug-Sensitive NTRK1 Rearrangements in Lung Cancer. *Nat. Med.* 2013, 19, 1469–1472. [CrossRef]
